QLGN
Qualigen Therapeutics, Inc. [QLGN] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
QLGN Stock Summary
Top 10 Correlated ETFs
QLGN
Top 10 Correlated Stocks
QLGN
In the News
QLGN Financial details
Company Rating
-
Market Cap
2.09M
Income
-13.7M
Revenue
3.23M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
31
Optionable
No
Shortable
Yes
Earnings
14 May 2024
P/E
-0.14
Forward P/E
-
PEG
0.03
P/S
0.6
P/B
-1.65
P/C
-
P/FCF
-0.38
Quick Ratio
0.39
Current Ratio
0.58
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.71
EPS next Y
-
EPS next Q
-
EPS this Y
-53.83%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-97.51%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
-34.72%
-
-
-
-
SMA20
-16.46%
SMA50
-24.67%
SMA100
-60.02%
Inst Own
-
Inst Trans
-
ROA
-458%
ROE
-632%
ROC
6.14%
Gross Margin
27%
Oper. Margin
-218%
Profit Margin
-427%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.2946-1.26
52W High
-
52W Low
-
RSI
47.14
Rel Volume
0.17
Avg Volume
63.88K
Volume
11.06K
Perf Week
9.91%
Perf Month
-19.32%
Perf Quarter
-61.83%
Perf Half Y
-64.71%
-
-
-
-
Beta
0.062
-
-
Volatility
0.12%, 0.39%
Prev Close
-1.93%
Price
3.55
Change
1.43%
Company Profile
- Volume Average 63.88K
- Market Capitalization 2.09M
- Employee 31
- CEO Mr. Michael S. Poirier
- Headquarters Carlsbad,CA,US
- IPO Date 2015-06-23
-
Website
https://www.qualigeninc.com 
Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.
